Evidence map›Paper›PMID 38716601›Full record

ArticleZhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi2024

[Clinical significance of IL-18 and IL-18-binding protein in bone marrow of patients with myelodysplastic syndrome].

T Wang, N Y Ran, Q L Chen, D L Liu, M T Zang, N B Li, X He, J Guan, R Fu, Z H Shao

Abstract readEnglish Abstract
PubMed Full text at PMC Publisher
In one paragraph

Article in Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

T WangDepartment of Hematology, General Hospital of Tianjin Medical University, Tianjin 300052, China Tianjin Key Laboratory of Bone Marrow Failure and Malignant Hemopoietic Clone Control, Tianjin 300052, China.
N Y RanDepartment of Hematology, General Hospital of Tianjin Medical University, Tianjin 300052, China Tianjin Key Laboratory of Bone Marrow Failure and Malignant Hemopoietic Clone Control, Tianjin 300052, China Changde Hospital, Xiangya School of Medicine, Central South University (The First People's Hospital of Changde), Changde 415003, China.
Q L ChenDepartment of Hematology, General Hospital of Tianjin Medical University, Tianjin 300052, China Tianjin Key Laboratory of Bone Marrow Failure and Malignant Hemopoietic Clone Control, Tianjin 300052, China.
D L LiuDepartment of Hematology, General Hospital of Tianjin Medical University, Tianjin 300052, China Tianjin Key Laboratory of Bone Marrow Failure and Malignant Hemopoietic Clone Control, Tianjin 300052, China.
M T ZangDepartment of Hematology, General Hospital of Tianjin Medical University, Tianjin 300052, China Tianjin Key Laboratory of Bone Marrow Failure and Malignant Hemopoietic Clone Control, Tianjin 300052, China.
N B LiDepartment of Hematology, General Hospital of Tianjin Medical University, Tianjin 300052, China Tianjin Key Laboratory of Bone Marrow Failure and Malignant Hemopoietic Clone Control, Tianjin 300052, China.
X HeDepartment of Hematology, General Hospital of Tianjin Medical University, Tianjin 300052, China Tianjin Key Laboratory of Bone Marrow Failure and Malignant Hemopoietic Clone Control, Tianjin 300052, China Department of Nephrology, Beijing Chaoyang Hospital, Beijing 100020, China.
J GuanDepartment of Hematology, General Hospital of Tianjin Medical University, Tianjin 300052, China Tianjin Key Laboratory of Bone Marrow Failure and Malignant Hemopoietic Clone Control, Tianjin 300052, China.
R FuDepartment of Hematology, General Hospital of Tianjin Medical University, Tianjin 300052, China Tianjin Key Laboratory of Bone Marrow Failure and Malignant Hemopoietic Clone Control, Tianjin 300052, China.
Z H ShaoDepartment of Hematology, General Hospital of Tianjin Medical University, Tianjin 300052, China Tianjin Key Laboratory of Bone Marrow Failure and Malignant Hemopoietic Clone Control, Tianjin 300052, China.

Funding

National Natural Science Foundation of China 81970115, 81970116Science and Technology Research Project of Tianjin Health Commission 16KG124Tianjin Association of Medicine and Health TJSYLJKXH004, TJSYLJKXH002, TJSYLJKXH013Tianjin Municipal Natural Science Foundation 18JCYBJC27200
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Bone MarrowIntercellular Signaling Peptides and ProteinsInterleukin-18Myelodysplastic SyndromesCD8-Positive T-LymphocytesClinical RelevanceFemaleHumansKiller Cells, NaturalMaleMiddle AgedIL18 protein, humanIntercellular Signaling Peptides and ProteinsInterleukin-18interleukin-18 binding proteinFree IL-18IL-18IL-18-binding proteinMyelodysplastic syndrome

Identifiers

PMID38716601
PMCPMC11078664

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.